Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — IPO Roadshow (September 2020)
33 slides from Scopus Biopharma's IPO roadshow presentation, September 2020
Slide 1: IPO Roadshow Presentation
DRAFT IPO Roadshow Presentation September 2020
Slide 2: Disclaimers
DRAFT Disclaimers Scopus Biopharma Inc. (“Scopus”) has filed an offering statement (including an offering circular) with the Securities and Exchange Commission (“SEC”) for the offering of Scopus shares of common stock to which this presentation relates. You should read the offering circular and othe
Slide 3: Overview
DRAFT Overview ➢ We develop transformational therapeutics targeting serious diseases with significant unmet medical needs ➢ Our lead drug candidate, CpG-STAT3siRNA (“CO-sTiRNATM”), is a Phase 1-ready immuno-oncology gene therapy for the treatment of multiple cancers ➢ Phase 1 clinical trial for B-ce
Slide 4: Overview (Cont.)
DRAFT Overview (Cont.) ➢ Pre-clinical testing on-going for cutaneous T-cell lymphoma and other solid tumors ➢ Additional Phase 1 clinical trials for B-cell NHL and other forms of cancer in combination with immune checkpoint inhibitors and/or CAR-Ts are planned for 2021 and H1 2022 ➢ We have an exclu
Slide 5: IPO Summary
DRAFT IPO Summary Issuer Scopus BioPharma Inc. Offering Size $5,500,000 (at mid-point of range) Common Stock Offered 1,000,000 shares Offering Price Per Share Expected to be between $5.25 and $5.75 per share Proposed Nasdaq Global Market Symbol “SCPS” Common Stock Outstanding After Offering 14,975,6
Slide 6: Investment Highlights
DRAFT Investment Highlights ➢ Potential game-changing treatment making STAT3 “druggable” for the first time ➢ Highly-differentiated scientific approach for treating cancer encompassing both immunotherapy and gene therapy ➢ Q1 2021 initiation of Phase 1 clinical trial for initial CO-sTiRNA indication
Slide 7: Transformational Therapeutics
DRAFT Transformational Therapeutics CO-sTiRNA MRI-1867 ➢ Our lead gene-silencing ➢ Proprietary, dual-action, cancer immunotherapy peripherally-restricted CB1 candidate receptor inverse agonist and iNOS inhibitor ➢ A novel, first-in-class drug targeting an undruggable ➢ Over activation of CB1 and can
Slide 8: Pipeline
KA SCOPUS Pipeline BIOPHARMA Program cat ate Pre-Clinical Testing +) IND-Enabling Studies +) rose) I CO-sTIRNA -cell Non-Hodgkin's Lymphoma
Slide 9: Value Building Milestones 2020 and 2021
DRAFT Value Building Milestones 2020 and 2021 Q4 2020 File IND for CO-sTiRNA in B-cell NHL Complete clinical lot manufacturing Generate initial pre-clinical results for CO-sTiRNA + checkpoint inhibitors H1 2021 Begin Phase 1 clinical trial for CO-sTiRNA in B-cell NHL Generate initial pre-c
Slide 10: Intellectual Property Portfolio
DRAFT Intellectual Property Portfolio ➢ Broad and growing portfolio of novel and proprietary compounds is covered by a broad patent portfolio ➢ Ongoing R&D with strategic partners allows for further IP creation ➢ We intend to file for Orphan Drug designation for some of our drug candidates which, if
Slide 11: Our Strategic Partners
DRAFT Our Strategic Partners ➢ Outstanding scientific and medical provenance with research and development based on pioneering discoveries at some of the world’s foremost research and academic institutions ➢ Technologies licensed from City of Hope National Medical Center, National Institutes of Heal
Slide 12: Experienced Biopharma Leadership
DRAFT Experienced Biopharma Leadership Paul E. Hopper Co-Chairman and Director Ashish P. Sanghrajka President and Director Aharon Schwartz, Ph.D. SAB Chairman Executive Chairman - Scopus Israel Morris C. Laster, M.D. SAB Member; Director and Senior Medical Advisor - Scopus Israel Raphael (Rafi) Hofs
Slide 13: Experienced Finance and Capital Markets Leadership
Experienced Finance DRAFT and Capital Markets Leadership Joshua R. Lamstein Co-Chairman and Director Robert J. Gibson, CFA Vice Chairman and Director David S. Battleman, M.D. Director David A. Buckel, CMA Director Ira Scott Greenspan Director David Weild IV Director 13
Slide 14: CO-sTiRNA is a Drug That Switches Off the STAT3 Gene
CO-sTiRNA is a Drug DRAFT That Switches Off the STAT3 Gene ➢ CO-sTiRNA acts by silencing STAT3 based on the gene therapy called RNA interference (RNAi) ➢ CO-sTiRNA is a targeted therapy directly to the cells of interest: the cancer cells and the associated immune cells ➢ CO-sTiRNA results in potent
Slide 15: Why Targeting STAT3 is So Important for Cancer Therapy
Why Targeting STAT3 is DRAFT So Important for Cancer Therapy ➢ STAT3 is a critical convergence point for many cancer-causing pathways, promoting cancer cell survival, proliferation and invasion by regulating several genes involved in cell growth and division ➢ When STAT3 proteins are activated by va
Slide 16: Blocking STAT3 in the Presence of CpG Induces Potent Antitumor Immune Responses
Blocking STAT3 in the Presence of DRAFT CpG Induces Potent Antitumor Immune Responses Proof-of-concept study in genetic model of STAT3 deletion (Mx-Cre/STAT3flox): STAT3 was removed from immune cells such as myeloid cells (DC, TAM, MDSC) and B cells but not from T cells B16 Melanoma Model Wild type
Slide 17: CO-sTiRNA: A Cancer Therapeutic Drug Candidate with Dual Activity
CO-sTiRNA: A Cancer Therapeutic Drug DRAFT Candidate with Dual Activity ➢ Dual activity blocks STAT3 in cancer cells and in tumor-associated immune cells while inducing antitumor immune responses ✓ Signal Transducer and Activator of Transcription 3 (STAT3) is a highly desirable target for cancer the
Slide 18: CO-sTiRNA: Preclinical In Vivo Efficacy Studies in B-cell Lymphoma
CO-sTiRNA: Preclinical In Vivo DRAFT Efficacy Studies in B-cell Lymphoma A20 Mouse Lymphoma Model • As a single agent: A- growth inhibitor of mouse solid tumors (1 mg/kg/PT)(Kortylewski Nat. Biotech. 2009) - T cell-mediated eradica,on of mouse AML (5 mg/kg/IV) (Hossain Blood 2014) - growth inhibi,on
Slide 19: CO-sTiRNA Induces Potent Antitumor Effects in Melanoma and Other Tumor Models
CO-sTiRNA Induces Potent Antitumor Effects DRAFT in Melanoma and Other Tumor Models 19 19
Slide 20: CO-sTiRNA Treatment Augments In Vivo Anti-Tumor Activity of Adoptively Transferred T Cells
DRAFT CO-sTiRNA Treatment Augments In Vivo Anti-TumorActivity of Adoptively Transferred T Cells Red shows tumor vasculature in A B C Live Mice “healthy tumors” B16 Melanoma Interferon gamma to measure how active T Cells are against melanoma Green shows tumor apoptosis; lack Herrmann of red signal in
Slide 21: CO-sTiRNA: Pharmacology and Toxicology Studies
CO-sTiRNA: DRAFT Pharmacology and Toxicology Studies ➢ No Cytokine Release Syndrome in vitro (human PBMC), no gross abnormalities in mouse and rat toxicology studies ➢ Completed initial toxicology study with CO-sTiRNA injected subcutaneously into male and female rats ➢ Subcutaneous injection (in rod
Slide 22: Overview of Phase 1 Clinical Trial for CO-sTiRNA
Overview of Phase 1 DRAFT Clinical Trial for CO-sTiRNA Indication Non-Hodgkin’s Lymphoma Population/ Indication(s): Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma Phase Phase 1, with expansion cohort Segment Relapsed/ Recurrent Therapy Status At initial treatment Sample Size 15 expected (4-24) Es
Slide 23: Phase 1 Clinical Trial Study Design and Proposed Endpoints
Phase 1 Clinical Trial DRAFT Study Design and Proposed Endpoints ➢ Study design is a modified rolling six dose escalation design to be performed in 2 dose levels, with dose escalation, de-escalation or expansion based on dose-limiting toxicities (DLT) ➢ There will be a 6-patient expansion at the rec
Slide 24: CO-sTiRNA Context
DRAFT CO-sTiRNA Context CpG Oligonucleotides STAT3 Antisense Small Molecule Alone Oligonucleotides Alone STAT3 Inhibitors ➢ Checkmate Pharmaceuticals ➢ Codiak Biosciences ➢ Glactone Pharma (+ anti-PD-1) (exosome formulation) ➢ GLG Pharma ➢ Exicure ➢ Immix Biopharma ➢ Ionis/AstraZeneca (+ anti-PD-L1)
Slide 25: Significant Investor Demand for Immuno-Oncology and Gene Therapy IPOs in 2020
Significant Investor Demand for DRAFT Immuno-Oncology and Gene Therapy IPOs in 2020 IPO Current (1) Gross Post-money Return Company Ticker Date Price Proceeds Market Cap. Price Market Cap. (IPO to Current) Immuno-Oncology Inhibrx, Inc. INBX 08/19/20 $17.00 $136.9 $641.0 $17.10 $644.8 0.6% Checkmate
Slide 26: MRI-1867
DRAFT MRI-1867 ➢ MRI-1867 is a proprietary, dual-action, peripherally-restricted NCE CB1 receptor (CB1R) inverse agonist and inhibitor of iNOS ➢ Over activation of CB1 and iNOS has been implicated in the pathophysiology of systemic sclerosis, including fibrosis of the skin, lung, kidney and heart ➢
Slide 27: MRI-1867: Noteworthy External Developments
DRAFT MRI-1867: Noteworthy External Developments ➢ On September 8, 2020, Corbus Pharmaceuticals announced negative top-line results from a Phase 3 clinical trial for its lead drug candidate, Lenabasum, for the treatment of systemic sclerosis ➢ Lenabasum showed no significant differences in the prima
Slide 28: Drug Development Costs
DRAFT Drug Development Costs 12-Month Post-IPO Estimated Drug Development Costs Amount Clinical Development of CO-sTiRNA $1,175,000 Sponsored Research Costs and Payments Relating to CO-sTiRNA License 725,000 IND preparation for CO-sTiRNA + Checkpoint Inhibitor 250,000 Pre-Clinical Development of MRI
Slide 29: Capital Strategy and Structure
DRAFT Capital Strategy and Structure ➢ Principal initial strategy for drug candidate portfolio is to in-license assets post-discovery from leading institutions and others ➢ Acquire/license rights to drug candidates for which significant capital already invested ➢ Reduces capital requirements of de n
Slide 30: Capital Strategy and Structure (Cont.)
DRAFT Capital Strategy and Structure (Cont.) ➢ Capital structure with embedded flexibility ➢ Optionality as to financing amounts, timing and pathways ➢ Optimized to drive growth in shareholder value ➢ Outstanding warrants structured to accommodate dynamic business strategy ➢ Advance drugs further al
Slide 31: Capitalization
DRAFT Capitalization Outstanding Securities Number Common Stock(1) 13,975,691 W Warrants(2) 8,686,438 Other Warrants(3) 250,000 Stock Options(4) 600,000 (1) As of July 7, 2020. Excludes shares which may become issuable upon satisfaction of milestones specified in connection with the acquisition of C
Slide 32: Key Takeaways
DRAFT Key Takeaways ➢ Potential game-changing treatment making STAT3 “druggable” ➢ CO-sTiRNA stands out as both immunotherapy and gene therapy ➢ Value-driving, near-term milestones ➢ Multi-billion dollar market opportunities ➢ High barriers to entry ➢ Attractive drug candidates with moderate near-te
Slide 33: Thank You
DRAFT Thank You Contacts: Robert J. Gibson, CFA Ashish P. Sanghrajka Vice Chairman President rgibson@scopusbiopharma.com asanghrajka@scopusbiopharma.com 33